Interv Akut Kardiol. 2011;10(2):58-60

Acetylosalicylic acid efficacy assessment in patients with stable coronary artery disease

Hana Ševčíková, Jan Vojáček, Josef Bis, Robert Ševčík
I. interní klinika, Fakultní nemocnice Hradec Králové, Univerzita Karlova Praha, Lékařská fakulta Hradec Králové

Inadequate platelet suppression by acetylosalicylic acid is a relatively well known phenomenon in cardiology. How to define it properly ?

Persistent high residual platelet reactivity or treatment failure seems to be the best term. There are several reasons for an inadequate platelet

suppression and several techniques may be used to assess platelet function and the effectiveness of antiplatelet therapy. The role of inflammation

and genetic polymorphisms in high residual platelet activity and atherothrombosis was studied with inconsistent results. There are still no

clinical data to support change in antiplatelet therapy in the correlation with the laboratory results in patients with coronary artery disease.

Keywords: platelet reactivity, antiplatelet agents, cardiovascular risk

Published: April 14, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ševčíková H, Vojáček J, Bis J, Ševčík R. Acetylosalicylic acid efficacy assessment in patients with stable coronary artery disease. Interv Akut Kardiol. 2011;10(2):58-60.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 1988; 12(6 Suppl A): 3A-13A.
    2. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanismus and clinical significance. Thromb Haemost 2002; 88: 711-715. Go to original source... Go to PubMed...
    3. Gurbel PA, Tantry US. The relationship of platelet reactivity to the occurrence of post- stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 2006; 7(Suppl 4): 387-395. Go to original source... Go to PubMed...
    4. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000. Go to original source... Go to PubMed...
    5. Krasopoulos G, Brister SJ, Beattie WS, Elliot RF, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-198. Go to original source... Go to PubMed...
    6. Dorsch MP, Lee JS, Lynch DR, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. The annals of pharmacotherapy, 2007. DOI 10.1345. Go to original source... Go to PubMed...
    7. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eurheartj 2006, 27: 647-665. Go to original source... Go to PubMed...
    8. Malý J. Rezistence na kyselinu acetylsalicylovou. Interv Akut Kardiol 2005; 4: 192-193.
    9. Karetová D, Bultas J. Rezistence na aspirin - laboratorní odchylka nebo klinický problém? Interní Med. 2005; 1: 10-13.
    10. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin Proc 2006; 81: 518-526. Go to original source... Go to PubMed...
    11. Cattaneo M. Laboratory detection of "aspirin resistance" what test should we use (if any)? Eur Heart J 2007; 28: 1673-1675. Go to original source... Go to PubMed...
    12. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007; 28(14): 1702-1708. Go to original source... Go to PubMed...
    13. Angiolillo DJ, Ortiz AF, Bernardo E, et al. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 2007; 49: 1505-1516. Go to original source... Go to PubMed...
    14. Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol 2005; 95: 805-808. Go to original source... Go to PubMed...
    15. Maree AO, Curtin RJ, Chubb A et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 10: 2340-2345. Go to original source... Go to PubMed...
    16. Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y. Effect of high dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 2009; 27: 24-28. Go to original source... Go to PubMed...
    17. Ševčíková H, Vojáček J, Pudil R, Malý J, Pecka M, Fátorová I. Rezistence na protidestičkovou terapii v kardiologické praxi. Interv Akut Kardiol 2006; 5: 256-258.
    18. Vojáček J, Malý M. Možnosti hodnocení funkce destiček. In: Vojáček J, Malý M, eds. Arteriální a žilní trombóza v klinické praxi. PA: Grada Publishing, 2004: 64-66.
    19. Weber AA, Adamzik M, Bachmann HS, et al. for the "Interdisciplinary Study Group - Clinical Pharmacology of Haemostasis". Methods to Evaluate the Pharmacology of Oral Antiplatelet Drugs. Herz 2008; 33: 287-296. Go to original source... Go to PubMed...
    20. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of doserelated effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164. Go to original source... Go to PubMed...
    21. Szczeklik A, Musial J, Undas A, et al. Aspirin resistance. J Thromb Haemost 2005; 3: 1655-1662. Go to original source... Go to PubMed...
    22. Gasparyan AY. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vascular Health and Risk Management 2010: 6 109-112. Go to original source... Go to PubMed...
    23. Peterson P. Aspirin resistance: Fact and fiction. http://japan.medscape.com/viewarticle/518858.
    24. Harrison P, Segal H, Silver L, et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function test. Platelets 2008; 19/2: 119-124. Go to original source... Go to PubMed...
    25. Ziegler S, Poulsen TS, Mickley H, et al. Von Willebrand factor release induced by endotoxin. J Laborat Clin Medicine 1989; 113: 118-122.
    26. Rex S, Beaulieu LM, Perlman DH, et al. Immune versus thrombotic stimulation of platelets differentially regulates signaling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97-110. Go to original source... Go to PubMed...
    27. Kvasnička J. Hereditary thrombophilias-recommendations for genetic testing in the clinical praxis. Cas Lek Cesk 2010; 149(10): 468-471. Go to PubMed...
    28. Pamukcu B, Oflaz H, Onur I, Hancer V, Yavuz S, Nisanci Y. Impact of genetic polymorphisms on platelet function and aspirin resistance. Blood coagulation and fibrinolysis, January 2010; 21/1: 53-56. Go to original source... Go to PubMed...
    29. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and non-responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403. Go to original source... Go to PubMed...
    30. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance amog stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965. Go to original source... Go to PubMed...
    31. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. The American Journal of Medicine 2007; 120: 631-635. Go to original source... Go to PubMed...
    32. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coagulation & Fibrinolysis 2008; 19/3: 235-239. Go to original source... Go to PubMed...
    33. Vojacek J, Sevcikova H, Sevcik R, Bis J, Pecka M. Increased platelet residual activity in patients treated with acetosalicylic acid is associated with increased tissue factor and decreased tissue factor pathway inhibitor plasma levels. International Journal of Cardiology (IJC-D-10-02871), ,v tisku".
    34. Capodanno D, Angiolillo DJ. Platelet monitoring for PCI - which test is the one to choose? Hämostaseologie 2009; 29: 376-380. Go to original source...
    35. Neubauer H, Kaiser AFC, Endres HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Medicine 2011; 9: 3. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.